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Abstract
Salmonella Typhi, first isolated in 1884, results in infection of the intestines and can end in death and disability. Due to
serious adverse events post vaccination, whole cell killed vaccines have been replaced with new generation vaccines. The
efficacy of Vi polysaccharide (ViPS) vaccine, a new generation, single-dose intramuscular typhoid vaccine was assessed in
Nepal in 1987. However, despite the availability of ViPS vaccine for more than 25 years, Nepal has one of the highest
incidence of typhoid fever. Therefore we collected information from hospitals in the Kathmandu Valley from over the past
five years. There were 9901 enteric fever cases between January 2008 and July 2012. 1,881 of these were confirmed typhoid
cases from five hospitals in the Kathmandu district. Approximately 70% of the cases involved children under 15 years old.
1281 cases were confirmed as S. Paratyphi. Vaccines should be prioritized for control of typhoid in conjunction with
improved water and sanitation conditions in Nepal and in endemic countries of Asia and Africa.
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effective vaccines has not received the attention and support
needed for controlling typhoid fever in low and middle income
countries. Moreover, the growing rate of multi-drug resistant
strains of S. Typhi in such settings has resulted in the increased
cost of treatment and the difficulty in managing the severity of
symptoms [2]. There are currently two licensed vaccines for
typhoid, Ty21a and Vi polysaccharide vaccine. Ty21a is an oral
live attenuated vaccine available in two formulations (enteric
coated capsule and a liquid formulation). Three doses of Ty21a in
enteric-coated capsules conferred 67% efficacy over three years of
follow-up and 62% protection over seven years of follow-up given
on an every other day schedule [9]. Currently only the entericcoated capsule formulation is manufactured. Ty21a is not WHO
prequalified- limiting its use through United Nations procurement
system such as UNICEF, the major donor of vaccines in
developing countries.
Twenty five years ago The New England Journal of Medicine
published the efficacy results of a clinical trial conducted in Nepal
using the Vi polysaccharide (ViPS) vaccine, one of the two licensed
typhoid vaccines [10]. ViPS vaccine is single dose and can be
stored at +2 to +8 degrees Celsius. The ViPS vaccine from one
manufacturer is WHO prequalified and hence could be purchased
in countries where vaccine supply is supported by UNICEF [11].
The vaccine has been used effectively in successful programs in a
number of developing countries [12,13] as well as in travel clinics
in wealthy and developed nations. In spite of the evidence for
effectiveness of Vi polysaccharide vaccine, the vaccine has not
been used routinely in Nepal, a country with one of the highest

Introduction
It has been almost 150 years since Eberth first identified
Salmonella Typhi (S. Typhi) for the first time; one of the very first
bacteria to be isolated at the time [1]. In spite of advances in
preventive medicine, humans continue to suffer from typhoid and
paratyphoid fever. The symptoms of typhoid fever range from very
mild cases of fever treated in outpatient clinics to severe forms that
result in intestinal perforation and hospitalization [2]. The current
global burden estimates indicate that more than 90% of typhoid
fever cases occur in countries in South and South East Asia [3].
Yet, the epidemiology and burden of typhoid fever are still not well
understood [4].
Typhoid fever presents challenges that range across its
diagnosis, treatment and prevention [6]. The most effective
interventions are improvements in water and sanitation, which
have resulted in the reduction of typhoid fever incidence in
developed nations where typhoid fever was once a major cause of
death [5]. Developments in water and sanitation in these settings
occurred in parallel to improvements in other areas, such as health
education and economic advancements. Similar methods of
control and eradication of the disease in many countries of Asia
demand considerable long-term socio-behavioral and economic
progress and resources which are scarce in these countries [6].
Thus, an interim preventive measure such as vaccination is critical
in these settings. There is evidence from around the world that the
disease has been successfully controlled through vaccination and
infrastructure development [7,8]. Yet, the use of available and
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was no direct contact of the study staff with the patients and data
was collected retrospectively and information collected from the
hospitals did not contain any identifiers of the patients. A written
or verbal informed consent was waived by Ministry of Health and
Population.

rates of endemic typhoid globally. Despite the absence of robust
surveillance data, there are reports of significant typhoid fever in
the country [14].
Here, we present data from hospitals in the Kathmandu
districts, one of the three in the valley, demonstrating higher
numbers of blood culture-confirmed typhoid fever cases. Our data
should elicit joint efforts from national and international organizations to control typhoid fever using existing vaccines in
conjunction with other preventive efforts to save significant health,
social and economic costs to the population in Nepal, who
contributed to the knowledge of typhoid vaccines more than two
decades ago. The use of typhoid vaccines is an important example
of obstacles and challenges faced before a licensed and effective
vaccine is made available to the people who need it the most [15].

Results
In the last five years, 30,586 febrile cases presented to at least
five hospitals in Kathmandu districts (Table 1). A total of 9,901
blood culture proven enteric fever cases was recorded in the 11
hospitals in the Valley (Table 2). The annual number of cases
ranged from a minimum of 947 in 2008 to a maximum of 3010 in
2011. Janamaitri Hospital reported the majority of cases, with
3,463 (35%) since 2008 (Table 2). There were 1881 cases of blood
culture confirmed typhoid cases reported from five hospitals
during the same time period. There is more than threefold
increase in typhoid fever cases with 165 cases in 2008 to 770 cases
in 2011 (Table 3). While typhoid fever is present throughout the
year, the majority of cases are clustered around the summer
months, from March to July. Among 3,857 cases for which the
patient age was available, 456 (12%), 1,155 (30%), 2,246 (58%)
cases were from younger than five years, between five and equal to
fifteen years and older than fifteen years, respectively (Table 4).

Methods
This 5-year retrospective hospital based data report is part of an
ongoing study in Nepal. This study examines the effectiveness of
the ViPS vaccine and its feasibility in public health programs as
part of advocacy efforts aimed at using existing vaccines for the
control of typhoid fever in Nepal. Data from blood culture
confirmed cases of typhoid fever were collected from hospitals
providing inpatient and outpatient services in the Kathmandu
District, Nepal. Out of 37 hospitals, 11 hospitals provided data on
enteric fever. The remaining hospitals did not have either
laboratory facilities for establishing proper blood culture confirmation or a regular information recording system for fever cases.
Surveillance staff visited the hospitals with a support letter from
the Child Health Division of the Ministry of Health and
Population and extracted 2008–2012 data from outpatients and
laboratory log books on: all fever cases reported, total blood
culture assessments performed on fever cases, total blood culture
positives, total enteric fever cases, and total typhoid cases
identified.
Data was available from hospitals where records of patients
were maintained. Where possible, we also collected information on
the age of the cases presenting to these hospitals. The age
categories of cases were divided into less than 5 years, 5–15 years
and more than 15 years. We also collected data, where available,
for each month of the year since 2008. We collected summary data
from each facility and did not collect information on patient
identification. Data was entered in Microsoft excel and analyzed in
STATA version 11.1.

Discussion
The data from the reporting hospitals clearly indicates that
enteric fever is a common infectious disease affecting all age
groups in Kathmandu Valley and Nepal, though adolescents and
adults are at the greatest risk. Typhoid and Paratyphoid fever are
significant infectious diseases in the population in the valley. In the
hospitals where information on fever and blood culture were
available, 4% to 8% of patients presenting with fever were typhoid
and 2% to 4% were paratyphoid fever. These numbers are
underestimates considering the sensitivity of blood culture
technique. In addition we were unable to collect uniform
information from all of the 37 hospitals that cater to infectious
diseases in the valley.
The population density in Kathmandu Valley has increased due
to migration from rural Nepal. This has developed a pressure on
water and hygiene infrastructure, resulting in compromised
conditions and the spread of infectious diseases [16]. Retrospective
data from various sources suggest that typhoid fever peaked in the
valley due to the civil unrest occurring outside of the valley in
2001, which led to a large, susceptible population moving into the
valley [17]. Other studies from the Kathmandu Valley have
reported high rates of first line anti-microbial resistance to S.
Typhi [14,18]. Antimicrobial resistance not only adds to the cost

Ethical considerations
The study was approved by Department of Child Health,
Ministry of Health and Population, government of Nepal. There

Table 1. Distribution of enteric fever by year comparing with overall fever cases.

S.No.

Description

2008

2009

2010

1

Total Number presented with fever

4474

7303

9466

2

Total number presented with fever and blood culture done

3967

89%*

4849

84%

6529

89% 8562

90%

3190

89%

3

Total number presented with fever, blood culture done and positive growth
(Typhi and paratyphi)

259

6%

382

7%

1052

14% 1091

12%

149

4%

4

Total number presented with fever, blood culture done and S. Typhi

165

4%

237

4%

515

7%

757

8%

67

2%

5

Total number presented with fever blood culture done and S. Paratyphi

94

2%

177

3%

569

8%

340

4%

106

3%

5762

2011

2012
3581

Note: data comes from four Hospitals – (AH, HAMS, KMC, KMH).
*percentages are based on number of febrile patients presenting to the hospitals.
doi:10.1371/journal.pone.0077974.t001
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Table 2. Annual distribution of enteric fever in Kathmandu,
Nepal.

Table 4. Age distribution of enteric fever cases annually in
Kathmandu Valley, Nepal.

2008 2009 2010 2011 2012* Total

Total Enteric
,5 years
fever cases

5–15 years

15 years

%

n

%

n

%

17

258

41

268

42

142

11

315

24

871

66

81

11

259

35

406

54

805

77

10

220

27

508

63

2012

347

51

15

103

30

193

56

Total

3857

456

Tribhuvan University Teaching
Hospital

161

364

80

70

35

710

N

STIDH

204

165

284

189

75

917

2008

631

105

IF Children Hospital

240

228

53

129

73

723

2009

1328

Janamaitri Hospital

0

809

934

1293 427

3463

2010

746

Army Hospital

125

168

322

269

129

1013

2011

Kathmandu Model Hospital

50

175

690

782

20

1717

Kathmandu Medical College

46

38

37

36

24

181

HAMS

38

33

35

33

0

139

OM Hospital

4

63

193

32

43

331

Nepal Police Hospital

64

87

120

98

70

439

Bir Hospital

19

73

59

79

38

268

Total

947

2203 2807 3010 934

9901

and difficulty of treatment, but also prolongs the duration of
treatment and may result in unwanted complications such as gut
perforation [19]. Despite the emergence of drug resistance,
availability of antimicrobials has markedly reduced typhoid fever
related mortality, a major initiator for government supported
efforts for setting priorities for the control of diseases. We were
unable to capture information on typhoid mortality due to a lack
of typhoid specific mortality surveillance.
Vaccination against typhoid fever alone is not sufficient for the
full control of the disease [7]. Instead, typhoid fever control
demands a comprehensive strategy that includes prevention of the
disease through hand washing, maintaining personal and environmental hygiene, adequate sewage treatment and availability of
safe and clean drinking water to reduce problems of water-borne
infections and the spread of enteric fever. In addition, as the world
has witnessed a decline in mortality due to availability of
antimicrobials, access to timely and appropriate clinical care also
helps in reducing complication rates due to typhoid and the costs
related to typhoid fever morbidity. The cost of the ViPS vaccine (9
USD per dose), that it can only be given to older than 2 years
population, challenges of delivery in routine public health
programs; and the widespread availability and use of antibiotics

are the reasons why government policy has not been developed for
typhoid vaccination. Moreover, long-term, infrastructure development strategies are necessary for curbing the spread of diseases,
as well as for maintaining the general health of the population.
The data on the effectiveness of ViPS vaccine provides a strong
rationale for its use among other strategies in meeting public
health prevention needs for controlling typhoid fever and is
relevant for the control of disease in the Kathmandu Valley.
It is quite poignant and ironic that, while the ViPS vaccine was
tested and licensed based on data from Nepal in 1987, the country
has not had the opportunity to use the vaccine in its immunization
program [10]. Unfortunately, the general public has not been well
informed about the use of the vaccine for preventing typhoid fever.
In addition, the cost of the locally available vaccine is prohibitively
expensive for most of the Nepali population. To address this issue,
a pilot typhoid vaccination project was conducted in the
Kathmandu Valley between 2010 and 2011. The results show a
high population demand for the prevention of the disease through
the use of vaccines. Following the pilot typhoid vaccination
project, there has been increased interest in and commitment from
the Ministry of Health and Population and District Public Health
Offices for introducing the ViPS vaccine in high risk populations.
Government officials closely follow World Health Organization
(WHO) recommendations for the use of vaccines and adhere to its
procurement guidelines, that is, pre-qualification standards for the
use and purchase of vaccines. The existing WHO pre-qualified
ViPS vaccine is presently too expensive for developing country
governments with their existing health budget. However, typhoid
fever is one of the priority diseases for the Global Alliance for
Vaccines and Immunization (GAVI), which, in its meeting in
September 2011, committed its support for conjugate typhoid
fever vaccines. A conjugate vaccine has an increased duration of
efficacy and may be used for children under two years old. There
are conjugate typhoid fever vaccines in the pipeline, two of them
are licensed for use in India. The WHO-prequalification of these
vaccines is still a few years away. Considering the burden of
typhoid fever in the Kathmandu Valley and in other parts of
South Asia, it is imperative to consider ways to support the use of
existing vaccines. Unquestionably, local public health leadership

Table 3. Annual distribution of typhoid fever cases by
hospitals in Kathmandu Valley, Nepal.

2009

2010

2011

2012* Total

Army Hospital

72

82

122

105

30

411

Kathmandu Model
Hospital

35

105

345

625

13

1123

Kathmandu Medical
College

40

33

33

11

24

141

HAMS

18

17

15

16

0

66

OM Hospital

0

31

81

13

15

140

Total

165

268

596

770

82

1881

*Data for 2012 is until October.
doi:10.1371/journal.pone.0077974.t003

PLOS ONE | www.plosone.org

2246

Note: Hospitals in above data: TH, IFCH, KMC, HHC, OH, and NPH.
TH- Tribhuvan University Teaching Hospital.
IFCH- International Friendship’s Children Hospital.
KMC- Kathmandu Medical College.
HHC- Helping Hands Community Hospital.
OH- Om Hospital.
NPH- Nepal Police Hospital.
AH- Army Hospital.
HAMS- Hospital for Advanced Medicine and Surgery.
doi:10.1371/journal.pone.0077974.t004

*data for full year of 2012 was not available at the time of data collection.
doi:10.1371/journal.pone.0077974.t002

2008

1155
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should play a vital role in addressing the typhoid control agenda,
but international experts and agencies have a strong influence in
ensuring access and support of the use of existing typhoid vaccines
in countries such as Nepal [20]. Access is a key word for which
international agencies need to assume accountability in order to
address the unmet public health needs of lower income
communities that continue to suffer from typhoid in spite of
having hosted trials that resulted in the licensure and use of such
vaccines in wealthy populations who can afford it.

Our data also does not consider blood culture sensitivity.
However, the cases of typhoid fever presented here are likely only
the tip of the iceberg with the actual incidence being possibly
much higher. There are other studies from the Kathmandu Valley
and from other parts of Nepal which indicate the pervasiveness of
typhoid fever in the country [14]. Data for the later quarter of
2012 was not available at the time this manuscript was written.
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